Breaking News, Collaborations & Alliances

Chime Biologics & Mabgeek Complete PPQ for MG-K10

Propels the monoclonal antibody into Phase III clinical trials for treating Th2-mediated inflammatory diseases.

Author Image

By: Charlie Sternberg

Associate Editor

Chime Biologics, a global CDMO, and Mabgeek, a clinical-stage innovative antibody drug development biotech, have successfully completed Process Performance Qualification (PPQ) for MG-K10, a humanized anti-IL-4Rα monoclonal antibody. This milestone propels the Phase III clinical trials for treating Th2-mediated inflammatory diseases such as moderate-to-severe atopic dermatitis (AD), asthma, rhinosinusitis, prurigo nodularis, esophagitis and chronic obstructive pulmonary disease (COPD). Chim...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics